Prognostic Value of a Novel Model for Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization

IF 2.9 4区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Journal of Clinical Laboratory Analysis Pub Date : 2025-09-05 DOI:10.1002/jcla.70095

Cailing Ye, Yaqiong Chen, Jiahao Chen, Zhongcheng Chen, Wensi Chen, Suqing Zhao, Bo Hu, Zhaoxia Li

{"title":"Prognostic Value of a Novel Model for Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization","authors":"Cailing Ye, Yaqiong Chen, Jiahao Chen, Zhongcheng Chen, Wensi Chen, Suqing Zhao, Bo Hu, Zhaoxia Li","doi":"10.1002/jcla.70095","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Hepatocellular carcinoma (HCC) patients who underwent transarterial chemoembolization (TACE) have heterogeneous clinical outcomes. Accurate prognosis prediction and risk stratification are crucial for individualized treatment. We sought to develop a novel prognostic model for overall survival (OS) that incorporated contemporary clinical and laboratory factors for estimating individual prognosis.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 180 HCC patients treated with TACE were used to identify the risk factors and generate prognostic models by Cox regression analyses. Model performance was evaluated by comparing it with the Tumor-Node-Metastasis (TNM) and Barcelona-Clinic Liver-Cancer (BCLC) staging systems.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A prognosis model (PI score), which consisted of neutrophil-lymphocyte ratio (NLR), γ-glutamyl transpeptidase (GGT), alpha-fetoprotein (AFP), and TNM stage, was constructed. The PI scores of each patient were calculated, and the patients were divided into subgroups based on their PI scores. The OS rate of patients in the low-risk group (PI < 0.87) was better than that of the patients in the high-risk group (PI ≥ 0.87), <i>p</i> < 0.001. Patients were then further divided into four stages: early stage (PI ≤ 0.49), middle stage (0.49 < PI ≤ 0.87), advanced stage (0.87 < PI ≤ 1.48), and end stage (PI > 1.48). There were statistically significant differences between the OS rates of the four groups (<i>p</i> < 0.001). The area under the ROC curve (AUROC) for PI score (0.746, 0.643–0.783) was higher than those of TNM (0.699, 0.620–0.763) and BCLC (0.692, 0.617–0.760).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The PI score had excellent predictive value for HCC patients undergoing TACE and was superior to TNM and BCLC.</p>\n </section>\n </div>","PeriodicalId":15509,"journal":{"name":"Journal of Clinical Laboratory Analysis","volume":"39 19","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcla.70095","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Laboratory Analysis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jcla.70095","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Hepatocellular carcinoma (HCC) patients who underwent transarterial chemoembolization (TACE) have heterogeneous clinical outcomes. Accurate prognosis prediction and risk stratification are crucial for individualized treatment. We sought to develop a novel prognostic model for overall survival (OS) that incorporated contemporary clinical and laboratory factors for estimating individual prognosis.

Methods

A total of 180 HCC patients treated with TACE were used to identify the risk factors and generate prognostic models by Cox regression analyses. Model performance was evaluated by comparing it with the Tumor-Node-Metastasis (TNM) and Barcelona-Clinic Liver-Cancer (BCLC) staging systems.

Results

A prognosis model (PI score), which consisted of neutrophil-lymphocyte ratio (NLR), γ-glutamyl transpeptidase (GGT), alpha-fetoprotein (AFP), and TNM stage, was constructed. The PI scores of each patient were calculated, and the patients were divided into subgroups based on their PI scores. The OS rate of patients in the low-risk group (PI < 0.87) was better than that of the patients in the high-risk group (PI ≥ 0.87), p < 0.001. Patients were then further divided into four stages: early stage (PI ≤ 0.49), middle stage (0.49 < PI ≤ 0.87), advanced stage (0.87 < PI ≤ 1.48), and end stage (PI > 1.48). There were statistically significant differences between the OS rates of the four groups (p < 0.001). The area under the ROC curve (AUROC) for PI score (0.746, 0.643–0.783) was higher than those of TNM (0.699, 0.620–0.763) and BCLC (0.692, 0.617–0.760).

Conclusions

The PI score had excellent predictive value for HCC patients undergoing TACE and was superior to TNM and BCLC.

Abstract Image

查看原文本刊更多论文

一种新的肝细胞癌经动脉化疗栓塞模型的预后价值。

背景：肝细胞癌（HCC）患者接受经动脉化疗栓塞（TACE）具有不同的临床结果。准确的预后预测和风险分层对个体化治疗至关重要。我们试图建立一种新的总生存（OS）预后模型，该模型结合了当代临床和实验室因素来估计个体预后。方法：对180例经TACE治疗的HCC患者进行Cox回归分析，确定其危险因素并建立预后模型。通过与肿瘤-淋巴结-转移（TNM）和巴塞罗那临床肝癌（BCLC）分期系统进行比较来评估模型的性能。结果：建立了由中性粒细胞-淋巴细胞比值（NLR）、γ-谷氨酰转肽酶（GGT）、甲胎蛋白（AFP）、TNM分期组成的预后模型（PI评分）。计算每位患者的PI评分，并根据PI评分将患者分为亚组。低危组患者的OS率（PI 1.48）。结论：PI评分对接受TACE的HCC患者具有极好的预测价值，优于TNM和BCLC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Laboratory Analysis 医学-医学实验技术

CiteScore

5.60

自引率

7.40%

发文量

584

审稿时长

6-12 weeks

期刊介绍： Journal of Clinical Laboratory Analysis publishes original articles on newly developing modes of technology and laboratory assays, with emphasis on their application in current and future clinical laboratory testing. This includes reports from the following fields: immunochemistry and toxicology, hematology and hematopathology, immunopathology, molecular diagnostics, microbiology, genetic testing, immunohematology, and clinical chemistry.